AMSER Case of the Month September 2020

71-year-old male with 1-month history of painless palpable retroareolar breast mass

Shiyi Li, MS4 - Perelman School of Medicine

Derek Lee, MD - Department of Radiology, University of Pennsylvania Health Systems

Linda White Nunes, MD, MPH - Department of Radiology, University of Pennsylvania Health Systems





Patient Presentation

- HPI: 71-year-old male presents with 1-month history of new painless palpable retroareolar right breast mass.
- Medical history: colorectal cancer s/p resection and chemoradiation (2007), hypertension and bilateral sciatica
- Family history: non-contributory
- Medications: gabapentin, ibuprofen
- Physical exam: ~1cm, non-tender, round, firm retroareolar mass of the right breast



What Imaging Should We Order?



ACR Appropriateness Criteria for palpable breast mass in male 25 years of age or older

Variant 3:


Male 25 years of age or older with indeterminate palpable breast mass. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
Mammography diagnostic	Usually Appropriate	\$\$
Digital breast tomosynthesis diagnostic	Usually Appropriate	**
US breast	May Be Appropriate	0
MRI breast without and with IV contrast	Usually Not Appropriate	0
MRI breast without IV contrast	Usually Not Appropriate	0


Mammography diagnostic and digital breast tomosynthesis were ordered to evaluate palpable right breast mass



Findings (unlabeled)



Findings: (labeled)




Digital breast tomosynthesis:

Left: Increased retroareolar density, consistent with gynecomastia.

Right: Increased retroareolar density, asymmetrically dense compared to left. Oval mass in retroareolar region in the anterior depth, corresponding to patient's palpable abnormality.



Findings: (labeled)



Ultrasound:

25 mm x 17 mm x 13 mm, oval, hypoechoic mass with circumscribed margins see in the retroareolar region of the right breast at 7 o'clock.

Associated features include internal vascularity (Doppler not shown).


Overall BI-RADS category: 4 – highly suspicious, biopsy recommended

RMSER

Final Dx:

Infiltrating moderately differentiated duct carcinoma with mucinous and micropapillary features.

Estrogen Receptor (ER) positive, Progesterone Receptor (PR) positive, HER2/neu oncogene expression negative



Histology: (A) Low power H&E demonstrating invasive and intraductal carcinoma; (B) High power H&E demonstrating mucinous features and cribriform architecture.



Male Breast Cancer Presentation and DDX

- Epidemiology
 - <0.5% of all annual breast cancer diagnoses in the US
 - Men are usually 5-10 years older than women at time of diagnosis
- Presentation
 - Painless firm mass, usually subareolar
 - Nipple involvement in 40-50% of cases
- Differential diagnosis
 - Lipoma ovoid breast masses comprised of fat, most common benign soft-tissue neoplasm
 - Gynecomastia bilateral symmetric breast enlargement with poorly defined borders
 - No skin changes or lymphadenopathy
 - Pseudogynecomastia increase in breast fat rather than glandular tissue
 - Infection localized and painful inflammation with systemic symptoms (fever and malaise)
 - Fibromatosis local tumors with no known potential for metastasis or differentiation
 - Granular cell tumor benign tumors from Schwann cells, most common in oropharynx or breasts



Risk Factors

- Genetic
 - Family history in 15-20% of patients
 - BRCA1/BRCA2 mutation
 - Higher risk with BRCA2: 6% lifetime risk of breast cancer with germline mutation
 - Klinefelter syndrome
 - High ratio of estrogen to testosterone
 - Gynecomastia
 - 19 and 58-fold increase in incidence of and mortality from breast cancer
 - Cowden syndrome (PTEN mutation)
 - Li-Fraumeni syndrome (p53 mutation)
 - Lynch syndrome (mismatch repair gene mutation)
- Acquired
 - Excess estrogen stimulation, hepatic dysfunction, obesity, marijuana use

SER

Management and Prognosis

- Management of male breast cancer is similar to female breast cancer with a few exceptions:
 - Early-stage cancer proceed with simple mastectomy rather than breastconserving therapy
 - Hormone receptor-positive disease receive adjuvant tamoxifen rather than aromatase inhibitor (AI)
 - Insufficient evidence to support AI monotherapy in men
 - Fewer side effects compared with AI
- 2018 SEER database analysis (289,673 breast cancer cases, 2054 men) worse prognosis compared to women
 - Risk of death is 41% higher
 - 5 and 10 year survival rate: 85 and 73% (compared to 90 and 85% in females)



References

Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678-687. doi:10.7326/0003-4819-137-8-200210150-00013

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. doi:10.3322/caac.21387

Liu N, Johnson KJ, Ma CX. Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis. Clin Breast Cancer. 2018;18(5):e997-e1002. doi:10.1016/j.clbc.2018.06.013

Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405-417. doi:10.1093/annonc/mdx651

Gnerlich JL, Deshpande AD, Jeffe DB, Seelam S, Kimbuende E, Margenthaler JA. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837-1844. doi:10.1245/s10434-010-1468-3

Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet. 1971;8(4):460-461. doi:10.1136/jmg.8.4.460

Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999;85(3):629-639. doi:10.1002/(sici)1097-0142(19990201)85:3<629::aid-cncr13>3.0.co;2-v